NCR Online Journal

30+ Active Companies working to develop 30+ Pipeline Therapies for Migraine Treatment Landscape | Major Companies- AbbVie, Trevena, Pear Therapeutics, Xoc Pharmaceuticals, and Others.

 Breaking News
  • No posts were found

30+ Active Companies working to develop 30+ Pipeline Therapies for Migraine Treatment Landscape | Major Companies- AbbVie, Trevena, Pear Therapeutics, Xoc Pharmaceuticals, and Others.

April 12
17:23 2023
30+ Active Companies working to develop 30+ Pipeline Therapies for Migraine Treatment Landscape | Major Companies- AbbVie, Trevena, Pear Therapeutics, Xoc Pharmaceuticals, and Others.

DelveInsight’s, “Migraine Pipeline Insight 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including Migraine clinical trials and nonclinical stage products. It also covers the Migraine pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Migraine Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Migraine collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Migraine Pipeline Report

 

  • DelveInsight’s Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.

 

  • The leading Migraine Companies includes Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.

 

  • Promising Migraine Pipeline Therapies includes Lasmiditan, Sumavel DosePro, Sumatriptan, ZNS, Eptinezumab, AMG334, Oral Prophylactic, Frovatriptan 2.5 mg, topiramate, Almotriptan Malate, and others.

 

  • The Migraine companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The Migraine pipeline therapies under development are focused on novel approaches to treat/improve Migraine.

 

To explore more information on the latest breakthroughs in the Migraine Pipeline treatment landscape of the report, click here @ Migraine Pipeline Outlook

 

Migraine Overview

Migraine is a neurological pain condition that affects millions of people. It is the most common neurological disease that has significant effects on the brain and consequently on behaviors associated with repeated migraine attacks. The stress of migraine is associated with premigraine, intermigraine, and postmigraine processes.

 

Recent Developmental Activities in the Migraine Treatment Landscape

 

  • In June 2021, Sosei Group Corporation announced the initiation of Phase I clinical study of HTL0022562 (also known as BHV3100), a novel, small-molecule CGRP receptor antagonist, for the treatment of migraine. (NCT04941989)

 

  • In March 2021, AbbVie announced that the US FDA accepted a new drug application (NDA) for atogepant for the preventive treatment of Migraines. The NDA approval was supported by data from a pivotal Phase III ADVANCE clinical trial, a pivotal Phase IIb/III study, and a Phase III long-term safety study.

 

  • In March 2021, Biohaven Pharmaceutical enrolled the first subject in Phase II/III clinical trial of oral zavegepant for the preventive treatment of migraine (NCT04804033). 

 

Request a sample and discover the recent advances in Migraine Ongoing Clinical Trial Analysis and Medications, click here @ Migraine Treatment Landscape

 

Migraine Emerging Drugs Profile

 

  • AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.

 

  • STS-101: Satsuma Pharmaceuticals

STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration.

 

  • Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

 

  • TNX1900: Tonix Pharmaceuticals

TNX-1900(Oxytocin), Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication.

 

Migraine Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Migraine. The companies which have their Migraine drug candidates in the most advanced stage, i.e. phase III include, Novartis.

 

For further information, refer to the detailed Migraine Unmet Needs, Migraine Market Drivers, and Market Barriers, click here for Migraine Ongoing Clinical Trial Analysis

 

Scope of the Migraine Pipeline Report

 

  • Coverage- Global

 

  • Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.

 

  • Migraine Pipeline Therapies- Lasmiditan, Sumavel DosePro, Sumatriptan, ZNS, Eptinezumab, AMG334, Oral Prophylactic, Frovatriptan 2.5 mg, topiramate, Almotriptan Malate, and others

 

  • Migraine Pipeline Segmentation: Product Type, Molecule Type, Mechanism of action, Route of administration

 

Dive deep into rich insights for drugs for Migraine Market Drivers and Migraine Market Barriers, click here @ Migraine Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Migraine: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Migraine– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. AXS-07: Axsome Therapeutics
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. STS-101: Satsuma Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. TNX1900: Tonix Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Migraine Key Companies
  21. Migraine Key Products
  22. Migraine – Unmet Needs
  23. Migraine – Market Drivers and Barriers
  24. Migraine – Future Perspectives and Conclusion
  25. Migraine Analyst Views
  26. Migraine Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Migraine Mergers and acquisitions, Migraine Licensing Activities @ Migraine Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/